Engineered tRNA Restored a Missing Protein in Cystic Fibrosis Models

A redesigned transfer RNA helped cells ignore a mistaken genetic stop signal and finish making a protein that is missing in some forms of cystic fibrosis. The researchers paired the RNA with lipid nanoparticles tailored for delivery to the lungs, then tested the combination in human airway cells, mice and patient-derived organoids.

Key Number: In human airway cells, restored CFTR activity persisted for more than 40 days after treatment.

A misplaced stop signal

Cells read messenger RNA in three-letter units called codons. Most specify an amino acid, while three tell the protein-making machinery to stop. A nonsense mutation places one of those stop instructions too early, leaving the cell with a shortened protein or none at all.

The team engineered suppressor transfer RNA, or sup-tRNA, to recognize the premature signal, insert an amino acid and allow protein production to continue. One chemical modification made the RNA more active and longer lasting while reducing unwanted innate immune activation.

Delivery was half the experiment

RNA cannot become a practical medicine unless it reaches the correct tissue. The researchers synthesized about 1,000 candidate lipids and selected a formulation that packaged the modified tRNA into nanoparticles. In preclinical tests, the particles carried their cargo to lung tissue and survived aerosolization, an early requirement for a possible inhaled treatment.

The approach restored CFTR production and function in human bronchial cells with common nonsense mutations. It also worked in animal experiments and in organoids grown from a patient whose complex combination of four CFTR mutations did not respond to existing drugs.

Why combination treatment mattered

In that patient-derived organoid, neither the modified tRNA nor the cystic fibrosis drug Trikafta produced much benefit alone. Together, they restored measurable CFTR function. The tRNA supplied full-length protein, while Trikafta helped that protein fold, reach the cell surface and work.

This matters because current CFTR modulators cannot repair a protein that was never completed. Roughly one in ten people with cystic fibrosis carry nonsense mutations that can leave them without enough protein for those drugs to act on.

What happens next

The immediate goal is to refine inhaled delivery and safety for cystic fibrosis before considering human studies. Because every nonsense mutation produces one of only three premature stop codons, a limited family of engineered tRNAs might eventually address the same error across many genes. The next evidence must show that this portability works without sacrificing precision.